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Abstract
Two distinct aspects of human immunodeﬁciency virus type 1 (HIV-1) biopathology with important implications for the management of
treated patients have emerged during the last decade: changes in relative viral ﬁtness, and viral tropism. First, it has been observed that
HIV-1 accumulates deleterious mutations leading to drug resistance and different degrees of reduction in relative ﬁtness during antiretro-
viral therapy (ART). Although the latter normally parallel a failure of ART resulting from selection of resistant mutants, the drop in viral
replication capacity may be beneﬁcial for the host. Moreover, speciﬁc antiviral compounds aimed at reducing viral ﬁtness could be deve-
loped. Analysis of the determinants of viral ﬁtness in highly evolving viral populations has shown that viral extinction may also be obtained
by forcing highly dynamic viral populations through increased (lethal) mutagenesis that abolishes viral replication (violation of the error
threshold). It could be of great interest in the near future to address this point with strategies speciﬁcally planned at the molecular level.
Furthermore, diagnostic evaluation limited to the master sequence has low predictive value in rapidly evolving viral populations. These
observations, together with the evidence that all of the methodologies currently used for ﬁtness analysis have important limitations,
strongly suggest that further research is warranted. This should use highly sensitive and ﬂexible technologies to evaluate viral ﬁtness
directly in vivo or ex vivo, not only for the dominant mutants, but also for minority variants. Second, discovery of the two main co-receptors
for HIV-1, CCR5 and CXCR4, has led to a better understanding of the interaction of the viral envelope with host cells and to the develop-
ment of novel therapeutic agents that inhibit viral entry. In this perspective, analysis of HIV-1 tropism has acquired a major diagnostic role.
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Introduction
A clearer understanding of virus–host relationships has
driven, in medical virology, the rapid development of speciﬁc
inhibitors of virus replication. The new data have also
allowed the planning of novel strategies that modify the equi-
librium between persistent viruses and their host, which is
unable to clear the pathogen. This is particularly important
for infections caused by RNA viruses characterized by fast
intra-host evolution. In replicating RNA viruses, the efﬁciency
of new genomic sequences is continuously assayed [1]. These
viruses display high mutation rates [2,3], and the major con-
sequence of this feature is that RNA virus populations are
composed of closely related, non-identical genomes, called
viral quasi-species [1]. Each viral quasi-species is normally
dominated by one most ﬁt genome (designated as the master
sequence), which competes with a mutant spectrum whose
components are represented according to their relative
ﬁtness in the environment where replication takes place [4].
This review analyses the biological and medical implications
of this concept, including its possible role in inﬂuencing
current and future therapeutic antiviral strategies. Moreover,
the biopathological implications of tropism changes and the
diagnostic role of human immunodeﬁciency virus type 1
(HIV-1) tropism testing will also be described and discussed.
Non-replicative and Replicative Genetic
Memory: Peculiarity of HIV-1 Quasi-species
RNA viruses display mutation rates in the range of 10)3 to
10)5 base substitutions per nucleotide copied [3]. These
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values are several orders of magnitude greater than those
observed in DNA viruses. Far from being victims of the error-
prone replication, RNA viruses have acquired mechanisms for
intra-host evolution, and the ﬁrst consequence of high muta-
tion rates is that RNA virus populations can be deﬁned as
closely related, non-identical genomes. Normally, these popu-
lations are dominated by one genome competing with a spec-
trum of variants; the master sequence is the most ﬁt genome,
and the other components of the virus population are repre-
sented according to their relative ﬁtness in the environment
[4]. Viral ﬁtness, the replicative adaptation of a virus to its
environment, has genetic and non-genetic determinants. These
determinants include viral replication capacity and multiple
environmental factors. Competition with other variants shar-
ing the same environment plays a central role in modifying the
ﬁtness of a viral population; in this perspective, viral ﬁtness
can be seen as a relative parameter that varies continuously in
a rapidly evolving viral population. These ﬁndings have gener-
ated a new way to approach virus evolution in vivo, and a
growing body of studies have addressed the biopathological
role of ﬁtness gain and ﬁtness loss of viral populations in vitro
[5]. Importantly from a medical point of view, the studies
addressing ﬁtness ﬂuctuations of highly mutating, persistent
and pathogenic viruses have also suggested antiviral strategies
targeting viral ﬁtness modulation. These aspects may be of
great interest in medical virology, both because more than
70% of the viral pathogens of humans discovered in the past
two decades are rapidly evolving RNA viruses, and because
several acute and persistent infections caused by RNA viruses
have great medical importance.
The HIV-1 quasi-species shows some peculiarities that
may strongly inﬂuence the dynamics of viral ﬁtness in
untreated subjects and in patients under treatment with anti-
retroviral compounds. Indeed, the replication cycle of HIV-1
favours the existence of two distinct types of genetic mem-
ory within the quasi-species: on the one hand, integrated
cDNA copies of viral RNA replicate as cellular genes, using
the cellular DNA polymerase and the proofreading repair
cellular activities; on the other hand, the error-prone replica-
tion cycle of HIV-1 permanently generates new variants. The
ﬁrst type of replication represents the non-replicative mem-
ory; the latter is similar to the replicative memory described
for other RNA viruses whose RNA replication cycle does
not include a DNA step, such as picornaviruses [6,7]. Inte-
grated cDNA copies of the HIV-1 genome constitute a res-
ervoir of viral sequences that, upon cellular activation, can
contribute new mutant distributions to the replicating pool
of the virus [8]. The existence of two types of genetic mem-
ory (non-replicative and replicative) has implications for the
HIV-1–host relationships [9] and, importantly, suggests the
need to develop analytical methodologies to determine not
only the dominant genomic sequences, but also minority ge-
nomes, as the latter genomes may reﬂect the evolutionary
history of the virus and supply information on its adaptation
to the host, as recently demonstrated for HIV-1 env
sequences [10]. Most of the techniques currently used in
diagnostic laboratories are not sensitive or ﬂexible enough
to be used in the routine analysis of minority sequences,
which represent 0.1–1% of a genome population. It is proba-
bly that only microarray-based strategies or recent sequence
analysis of the viral quasi-species speciﬁcally optimized for
the detection of viral variants can deal with this aspect, thus
allowing a predictive evaluation of the efﬁcacy of the treat-
ments [11].
Laboratory Methods for Viral Fitness
Viral ﬁtness is a relative parameter and can be evaluated:
(i) for a speciﬁc genomic region after cloning of this region
into a standard viral backbone (molecular clone); (ii) for a
viral isolate (biological clone); or (iii) for a virus population
obtained from an infected patient. The major advantage of
using molecular clones is that the ﬁtness changes can be
directly linked to the modiﬁcations in the cloned viral
sequence. The major advantage of using a viral isolate is that
the viral regions are present in the normal context, thus
including all of the potential compensatory mutations. Owing
to the central role of the ecosystem as a determinant of viral
ﬁtness in vivo, in vitro studies have obvious important limita-
tions in modelling the environment adequately. For this
principal reason, the ideal strategy to measure viral ﬁtness is
analysis of the competition of two or more variants directly
in vivo by tracking the relative proportion of each variant
over time. However, viral ﬁtness is rarely assayed in vivo,
principally because of the technical aspects, including the
need to sample many different tissue sources at frequent
time-points, and to develop molecular methodologies that
are reliable, sensitive and speciﬁc for individual variants.
An animal model system (such as the SCID-hu thy/liv
mouse model) carrying human fetal thymic and kidney tissues
[12] has been proposed as a model with which to evaluate
viral ﬁtness. A similar method has been proposed for hepati-
tis C virus. However, although the SCID-hu thy/liv mouse
supports HIV-1 replication, it cannot be considered to be a
reliable alternative to in vivo ﬁtness assays, being a model sys-
tem far from the complexity of HIV-1 infection of humans. In
the past few years, a number of ex vivo strategies have been
developed to evaluate the ﬁtness of individual viral variants,
including HIV-1 variants resistant to antiviral compounds of
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different classes. These assays include: (i) analysis of the rep-
lication capacity of recombinant viruses over a single replica-
tion cycle (either by limiting the duration of culture or by
using potent inhibitors that block a second round of infec-
tion); (ii) analysis of the replication capacity as measured by
testing the amount of virus produced over time; and (iii)
competition experiments (two strains are accurately quanti-
ﬁed and used in a mixed infection). Although crude estimates
of viral ﬁtness are possible by the use of viral growth kinetics
assays [13], small differences in the replication of HIV-1, such
as those conferred by single base changes, are not accurately
detected with non-competitive approaches [14]. A consensus
in the scientiﬁc community on the experimental strategy
used for viral ﬁtness analysis is important if this parameter is
going to be used in the clinical monitoring of infected
patients. Most of the assays described in the past few years
have a number of limitations; as a consequence of this, con-
tradictory results have been obtained in some cases, depend-
ing on the assay used in each study. Currently, competitive
methods, and principally the applications that are capable of
detecting small differences in viral replication capacity, should
be preferred to non-competitive techniques in evaluating the
ﬁtness of viral variants [14].
Biopathological and Clinical Role of HIV-1
Fitness: Fitness Proﬁle and Antiviral
Therapy
Studies on the mechanisms involved in competition between
viral strains can lead to a greater understanding of the forces
driving inter-host and intra-host virus evolution. Indeed,
important ﬁtness modiﬁcations may occur in response to
environmental changes. A large body of studies involve moni-
toring of HIV-1 infection in patients under combinatorial an-
tiretroviral therapy (ART). In these patients, the selection of
drug-resistant viral strains bearing speciﬁc resistance muta-
tions has frequently been observed [15]. When ART is inter-
rupted, drug-resistant variants are rapidly replaced [16] by
wild-type HIV-1. Interestingly, it has been observed that
most drug-resistant viral strains selected under treatment,
although capable of replicating efﬁciently in the presence of
drugs, show reduced viral ﬁtness as compared with wild-type
clones [13,17]. It has also been observed that further accu-
mulation of compensatory mutations (secondary mutations)
allows drug-resistant, less ﬁt, clones to evolve as a more ﬁt
virus. This phenomenon has been also documented in vivo in
patients with HIV-1 infection undergoing therapy with prote-
ase inhibitors (PIs) and with selection of drug-resistant viral
variants; in a number of cases, HIV-1 strains harbouring
PI resistance mutations may persistently replicate, despite a
change to a PI-sparing regimen [18]. This apparent abnor-
mality suggests that protease sequences have recovered
sufﬁcient functionality (and a consequent ﬁtness gain) in
these cases. A similar pattern of ﬁtness changes paralleling
selection of resistance mutations and subsequent accumula-
tion of secondary changes has been described in HIV-1 vari-
ants resistant to the integrase inhibitor raltegravir [19,20].
Overall, these data suggest that, despite the fact that selec-
tion of resistant viral mutants is frequent in vitro and in vivo
under the strong selective pressure of antiviral compounds,
rapidly evolving RNA viruses normally pay a cost in terms of
replication capacity. These data also suggest the possibility
of developing strategies to modulate viral ﬁtness in the
presence of drugs through resistance generation.
It has been observed that mutation K65R occurring in a
functionally important area of the HIV-1 reverse transcrip-
tase (RT) may be selected in vitro (and less frequently in vivo)
by several nucleoside/nucleotide inhibitors of HIV-1 replica-
tion [21]. This mutation confers resistance and cross-resis-
tance to several members of this class of compounds, and
reduces viral replication capacity. Importantly, HIV-1 RTs
bearing the K65R mutation are more susceptible to zidovu-
dine than is the wild-type sequence. This has suggested inter-
esting therapeutic strategies that use resistance generation
to select a replicating virus variant that is more easily elimi-
nated by other compounds. An additional interesting exam-
ple is provided by the mutation M184V in the HIV-1 RT
gene. This mutation is selected during treatment with lamivu-
dine, and is associated with alterations of various mecha-
nisms related to RT functions [22], including a reduction in
HIV-1 replication capacity. In a recent prospective study,
two groups of HIV-1 patients (all harbouring a lamivudine-
resistant virus) were evaluated: a ﬁrst group of patients
undergoing treatment interruption, and a second group
undergoing lamivudine monotherapy [23,24]. Recovery of
HIV-1 ﬁtness was observed after 48 weeks in the patients
under treatment interruption, but not in the subjects main-
tained on lamivudine monotherapy. Interestingly, and despite
sustained viral replication in both groups, loss of CD4+
T-cells was signiﬁcantly higher in the treatment interruption
group than in the lamivudine group. In summary, these data
indicate that, in patients harbouring a lamivudine-resistant
virus, continued administration of the drug leads to better
immunological and clinical outcomes than complete therapy
interruption. These results strongly suggest that, in HIV-1
infection, a virus mutant with low ﬁtness may also have a
lower pathogenic potential than wild-type HIV-1, and that
intentional reduction of viral ﬁtness with speciﬁc com-
pounds may be beneﬁcial for the host. From this perspective,
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continued therapy after the emergence of drug-resistant vari-
ants may be considered as an environmental modiﬁcation for
the maintenance of a less ﬁt virus variant.
A sizeable percentage of multi-experienced patients still fail
to achieve durable virological control, owing to the absence
of more than two active drugs in their regimen. According to
the international guidelines, before starting with a new regi-
men, the current indication in these cases is the maintenance
of the holding regimen (which is useless and probably toxic)
or therapy interruption. Indeed, if the CD4 count is high
enough to minimize the risk of clinical progression, delaying
the treatment change by introducing a ‘partial break’ with a
drug that maintains a low replication capacity of the virus
may be an important alternative therapeutic opportunity. This
strategy can also offer the advantage of reducing the toxicity
associated with the ongoing regimen, and could possibly lead
to having more options (novel compounds) when the new
regimen has to be introduced. Importantly, the reduced
ﬁtness of a mutant virus can increase the chance of achieving
an undetectable viral load with a new combination [24]. In
this perspective, a holding regimen conceived as a transition
between a failing combination and a new effective and fully
suppressive ART may be a possible step in the salvage strat-
egy for multi-experienced patients. In keeping with this, a
recent study showed that lamivudine or emtricitabine mono-
therapy is better than treatment interruption in patients who
are failing their current ART and whose virus already har-
bours the M184V mutation [25]. In particular, monotherapy
with emtricitabine shows that a compound used alone at a
very low dose is sufﬁcient to maintain, through selective pres-
sure, the M184V mutation in the replicating virus [26]. This
study also shows that, although leading to higher viral
rebound, the once-weekly administration of emtricitabine is
as effective as once-daily lamivudine in slowing the decline in
CD4 cell count. Together, these ﬁndings demonstrate that
the reduced ﬁtness diminishes the pathogenic potential of the
virus, and explain the conserved immune function despite the
higher viraemia. Recent ﬁndings [27] suggest that, in the
absence of drugs that maintain the M184V mutation, a 4–8%
of reduction in viral ﬁtness is observed in comparison with
wild-type strains, thus strengthening the hypothesis that it is
the decrease in virus pathogenicity rather than the residual
antiviral activity of the drug that drives the viro-immunologi-
cal dynamics in this setting [28].
HIV-1 Fitness and the Immune Response
The humoral and cellular immune response of the host is a
natural selective constraint operating during persistent virus
replication in vivo. Although acutely infecting viruses have the
chance to escape the host in a very short time, persistent
viruses are forced to cope with the adaptive host immune
response, which the virus itself must modulate, disrupt or
evade by genetic variation. The ability of the virus to escape
from cytotoxic T-cells and neutralizing antibodies without a
marked reduction in ﬁtness can be crucial for persistence
and disease progression. The antibody response is particu-
larly intriguing, as recent technological advances have made
possible the generation of a large number of human or
humanized monoclonal antibodies, which can be safely
administered to patients and that can constitute a novel class
of drugs for antiviral therapy in many cases [29]. Viruses that
persistently infect the host are usually endowed with regions
that can elicit neutralizing antibodies, but these regions
evolved in such a way that they can be easily mutated with-
out affecting viral ﬁtness. Recent reports have given a precise
measure of this interplay, demonstrating how, during HIV-1
infection, antibodies present in serum are not able to neu-
tralize the contemporary virus, while having neutralizing
activity against prior variants; conserved viral regions that
are difﬁcult to mutate and that are able to elicit useful anti-
bodies are present, but usually fail to elicit a strong response
in the majority of patients, as shown by recent reports
describing how a small number of HIV-1-infected subjects
producing broad cross-neutralizing antibodies can remain
asymptomatic [30]. It will be important to evaluate the role
of this broad neutralizing potential in modifying viral ﬁtness
in vivo.
The Extinction of a Virus Pathogen by
Violation of the Error Threshold
In the past few years, the idea of evaluating, at least for
infections with highly variable RNA viruses, novel antiviral
strategies aimed at determining a violation of the error
threshold (error catastrophe) in the replicating viral popula-
tion has been actively pursued [31]. Indeed, experimental
demonstration of this concept was initially obtained with
poliovirus and vesicular stomatitis virus. More recently, pro-
mutagenic nucleoside analogues were used to abolish viral
replication in HIV-1 infection in vitro [32]; in these studies,
the term ‘lethal mutagenesis’ was used to describe the muta-
gen-dependent drop in virus replication capacity. Finally, it
has recently been demonstrated that a cytidine deaminase
able to induce G to A hypermutation in newly synthesized
viral DNA (namely, apolipoprotein B mRNA editing enzyme
catalytic polypeptide-like 3G) may act as an endogenous
inhibitor [33], and that its effect can be counteracted by the
CMI Clementi and Lazzarin HIV-1 ﬁtness and tropism 1535
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1532–1538
HIV-1 Vif protein. Overall, this suggests that the Vif-depen-
dent mechanism could be exploited to drive HIV-1 towards
lethal mutagenesis.
HIV-1 Tropism, Tropism Testing, and
Correlates of Tropism Changes
Early after the discovery of HIV-1, it was observed that, after
primary HIV-1 infection, the vast majority of patients har-
bour a virus that efﬁciently infects macrophages and primary
lymphocytes, but not immortalized T-cell lines (these strains
were designated M-tropic viruses). Later in infection, more
cytopathic variants can be isolated. These variants, named T-
tropic viruses, have acquired the ability to replicate in
immortalized T-cell lines, but have lost the ability to infect
macrophages (these strains were named T-tropic viruses).
Because viral replication in these T-cell lines causes cyto-
pathic changes and syncytium formation, such isolates are
also named syncytium-inducing viruses. In contrast, M-tropic
viruses do not replicate in T-cell lines, and hence are named
non-syncytium-inducing viruses. More recently, when the
role of CCR5 and CXCR4 in HIV-1 entry was discovered, it
became apparent that viruses with the syncytium-inducing
phenotype preferentially use CXCR4 co-receptors, which
are expressed on MT-2 cells, whereas non-syncytium-induc-
ing strains use CCR5 co-receptors, which are absent from
this particular cell line. Viruses that preferentially use CCR5
as co-receptor are named R5 viruses; those that use CXCR4
are named X4 viruses. Because it is difﬁcult to distinguish
mixtures of R5 and X4 viruses from dual-tropic strains with
the currently available assays, viruses that are capable of
using both CCR5 and CXCR4 co-receptors are often
referred to as dual/mixed viruses.
Indeed, the discovery of the two main co-receptors for
HIV-1, CCR5 and CXCR4, has led to a better understanding
of the interaction of the viral envelope with host cells and
the development of novel therapeutic agents that inhibit viral
entry. HIV-1 entry into susceptible cells is initiated by attach-
ment of the surface subunit of the envelope glycoprotein
(gp120) to CD4 molecules on the cell surface. Subsequently,
binding of gp120 to a speciﬁc C-C or C-X-C chemokine
receptor triggers conformational changes of the envelope
transmembrane glycoprotein (gp41) that lead to membrane
fusion and entry of the viral core particle into the cell.
Although a number of chemokine receptors can be utilized
by HIV-1 for entry in vitro, the two most signiﬁcant co-recep-
tors in vivo are CCR5 and CXCR4 [34]. In this context, viral
tropism assays play an important role in identifying patients
who are candidates for treatment with entry inhibitors and
in the ongoing development of co-receptor antagonists. In
addition, epidemiological data on co-receptor usage are cru-
cial for elucidating the relationship between co-receptor
usage and disease progression.
At present, there are several methods with which to
determine HIV-1 tropism, but it is unclear which will prove
the most appropriate for routine clinical use. Recently, posi-
tive results have been obtained in studies aimed at evaluating
the efﬁciency of genotypic testing [35]. However, each of
these approaches has advantages and limitations, and both
share the common challenge of detecting low levels of X4
viruses present as minority variants in the viral quasi-species.
In conclusion, since the identiﬁcation of CCR5 and
CXCR4 co-receptors, much progress has been made in the
development of tropism assays and understanding the com-
plex relationship between viral tropism and HIV-1 disease.
With the advent of chemokine receptor antagonists, there is
additional impetus to decipher the complex determinants of
co-receptor usage, and the mechanisms driving the evolution
of X4 viruses. In this perspective, tropism assays are an
important tool in these investigations, and in the clinical man-
agement of HIV-1 infection.
Concluding Remarks
Most persistent RNA viruses, including HIV-1, are in equilib-
rium between two events: immune recognition, and hyper-
mutation that generates lethal viral variants unable to infect
efﬁciently. Strategies aimed at selecting deleterious mutations
in the infecting viral population drive the virus to ﬁtness loss.
In HIV-1 infection, increased replication efﬁciency expands
viral diversity. Evidence that a beneﬁcial effect for the host is
obtained by maintaining resistance mutations capable of inﬂu-
encing viral ﬁtness highlights the role of impaired viral repli-
cation capacity as an additional potential target of modern
antiviral strategy [36]. Both antivirals and monoclonal anti-
bodies targeting crucial structures or important functional
proteins of the virus can efﬁciently provide a strong selective
pressure for mutations that inﬂuence viral ﬁtness in rapidly
evolving RNA viruses; these compounds can also be com-
bined to maintain the virus under strong selective pressure.
In this context, addressing viral ﬁtness by using, in parallel,
different therapeutic tools may actually be viewed as a new
frontier of antiviral treatment. A ﬁnal answer to the question
of whether viral ﬁtness could be a reliable antiviral target
may be provided in the near future by the clinical evaluation
of compounds speciﬁcally developed to curb efﬁcient viral
replication capacity, thus driving virus evolution in vivo to
important and persistent ﬁtness loss. On the other hand,
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modiﬁcations of the HIV-1 tropism that is frequently
observed during the natural history of the infection may
strongly inﬂuence treatment options. All of this not only
highlights the important diagnostic role of the two virological
parameters of viral ﬁtness and tropism, but also conﬁrms
that a clearer understanding of virus–host relationships could
be of great importance in the development of new antiviral
strategies.
Acknowledgements
The studies of the authors presented in this article were par-
tially supported by grants of the Italian Ministry of University
and of the Italian Ministry of Health.
Transparency Declaration
None of the authors has any potential conﬂict of interest or
any ﬁnancial relationship relevant to this article to disclose.
References
1. Eigen M, Biebricher C. Sequence space and quasispecies distribution.
In: Domingo E, Ahlquist P, Holland J, eds. RNA genetics, Vol. 3. Boca
Raton, FL: CRC Press, 1988; 211–245.
2. Domingo E, Holland J. RNA virus mutation and ﬁtness for survival.
Annu Rev Microbiol 1997; 51: 151–178.
3. Drake J, Holland J. Mutation rates among RNA viruses. Proc Natl Acad
Sci USA 1999; 96: 390–393.
4. Domingo E, Holland J, Biebricher C, Eigen M. Quasispecies: the con-
cept and the word. In: Gibbs A, Calisher C, Garcia-Arenal F, eds.
Molecular basis of virus evolution. Cambridge: Cambridge University
Press, 1995; 171–180.
5. Lazaro E, Escarmis C, Perez-Mercader J et al. Resistance of virus to
extinction on bottleneck passages: study of a decaying and ﬂuctuating
pattern of ﬁtness loss. Proc Natl Acad Sci USA 2003; 100: 10830–
10835.
6. Ruiz-Jarabo C, Arias A, Baranowski E et al. Memory in viral quasispe-
cies. J Virol, 2000; 74: 3543–3547.
7. Ruiz-Jarabo C, Arias A, Molina-Paris C et al. Duration and ﬁtness
dependence of quasispecies memory. J Mol Biol 2002; 315: 285–
296.
8. Crandall K. The evolution of HIV. Baltimore, MD: The Johns Hopkins
University Press, 1999.
9. Briones C, Domingo E, Molina-Paris C. Memory in retroviral quasi-
species: experimental evidence and theoretical model for human
immunodeﬁciency virus. J Mol Biol 2003; 331: 213–229.
10. Bagnarelli P, Vecchi M, Burighel M et al. Genotypic and phenotypic
correlates of the HIV-1 env gene evolution in infected children with
discordant response to antiretroviral regimens. AIDS Res Hum Retrovi-
ruses 2004; 12: 1308–1315.
11. Gerry N, Witowski N, Day J et al. Universal DNA microarray
method for multiplex detection of low abundance point mutations.
J Mol Biol 1999; 292: 251–262.
12. Namikawa R, Kaneshima H, Lieberman M et al. Infection of the
SCID-hu mouse by HIV-1. Science, 1998; 242: 1684–1686.
13. Menzo S, Monachetti A, Balotta C et al. Processivity and drug-depen-
dence of HIV-1 protease: determinants of viral ﬁtness in variants
resistant to protease inhibitors. AIDS 2003; 17: 663–671.
14. Quinones-Mateu M, Arts E. Fitness of drug resistant HIV-1:
methodology and clinical implications. Drug Resist Updat 2002; 5:
224–233.
15. Nijhuis M, Deeks S, Boucher C. Implications of anti-retroviral resis-
tance on viral ﬁtness. Curr Opin Infect Dis 2001; 14: 29–37.
16. Deeks S, Wrin T, Liegler T et al. Virologic and immunologic conse-
quences of discontinuing combination antiretroviral-drug therapy in
HIV-infected patients with detectable viremia. N Engl J Med 2001;
344: 472–478.
17. Clavel F, Race E, Mammano F. HIV drug resistance and viral ﬁtness.
Adv Pharmacol 2000; 49: 41–66.
18. Boeri E, Gianotti N, Canducci F et al. Evolutionary characteristics of
HIV type 1 variants resistant to protease inhibitors in the absence of
drug-selective pressure. AIDS Res Hum Retroviruses 2003; 19: 1151–
1153.
19. Canducci F, Sampaolo M, Marinozzi MC et al. Dynamic patterns of
human immunodeﬁciency virus type 1 integrase gene evolution in
patients failing raltegravir-based salvage therapies. AIDS 2009; 20:
455–460.
20. Canducci F, Marinozzi MC, Sampaolo M et al. Genotypic/phenotypic
patterns of HIV-1 integrase resistance to raltegravir. J Antimicrob
Chemother 2010; 65: 425–433.
21. Weber J, Chakraborty B, Weberova J et al. Diminished replicative
ﬁtness of primary human immunodeﬁciency virus type 1 isolates
harboring the K65R mutation. J Clin Microbiol 2005; 43: 1395–1400.
22. Diallo K, Marchand B, Wei X et al. Diminished RNA primer usage
associated with the L74V and M184V mutations in the reverse trans-
criptase of human immunodeﬁciency virus type 1 provides a possible
mechanism for diminished viral replication capacity. J Virol 2003; 77:
8621–8632.
23. Castagna A, Danise A, Menzo S et al. Lamivudine monotherapy in
HIV-1-infected patients harbouring a lamivudine-resistant virus: a ran-
domized pilot study (E-184V study). AIDS 2006; 20: 795–803.
24. Gianotti N, Tiberi S, Menzo S et al. HIV-1 replication capacity and
genotype changes in patients undergoing treatment interruption or
lamivudine monotherapy. J Med Virol 2008; 80: 201–208.
25. Nozza S, Galli L, Visco F et al. Raltegravir, maraviroc, etravirine: an
effective protease inhibitor and nucleoside reverse transcriptase
inhibitor-sparing regimen for salvage therapy in HIV-infected patients
with triple-class experience. AIDS 2010; 27: 924–928.
26. Soria A, Danise A, Galli L et al. Viro-immunological dynamics in HIV1
infected subjects receiving once-daily emtricitabine to delay treat-
ment change after failure: a pilot study. J Clin Virol 2010; 47: 253–
257.
27. Paredes R, Sagar M, Marconi VC et al. In vivo ﬁtness cost of the
M184V mutation in multidrug resistant HIV in absence of lamivudine.
J Virol 2009; 83: 2038–2043.
28. Campbell TB, Shulman NS, Johnson SC. Antiviral activity of lamivu-
dine in salvage therapy for multidrug resistant HIV 1 infection. Clin
Infect Dis 2005; 41: 236–242.
29. Burioni R, Perotti M, Mancini N, Clementi M. Perspectives for the
utilization of neutralizing human monoclonal antibodies as anti-HCV
drugs. J Hepatol 2008; 49: 299–300.
30. Dhillon AK, Donners H, Pantophlet R et al. Dissecting the neutraliz-
ing antibody speciﬁcities of broadly neutralizing sera from human
immunodeﬁciency virus type 1-infected donors. J Virol 2007; 81:
6548–6562.
31. Eigen M. Error catastrophe and antiviral strategy. Proc Natl Acad Sci
USA 2002; 99: 13374–13376.
CMI Clementi and Lazzarin HIV-1 ﬁtness and tropism 1537
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1532–1538
32. Harris KS, Brabant W, Styrchak S et al. KP-1212/1461, a nucleoside
designed for the treatment of HIV by viral mutagenesis. Antiviral Res
2005; 67: 1–9.
33. Zhang H, Yang B, Pomerantz RJ et al. The cydine deaminase CEM15
induces hypermutation in newly synthesized HIV-1 DNA. Nature
2003; 424: 94–98.
34. Tsibris AMN, Kuritzkes DR. Chemokine antagonists as therapeutics:
focus on HIV-1. Annu Rev Med 2007; 58: 13.1–13.15.
35. Svicher V, D’Arrigo R, Alteri C et al. Performance of genotypic
tropism testing in clinical practice using the enhanced sensitivity
version of Troﬁle as reference assay: results from the OSCAR Study
Group. New Microbiol 2010; 33: 195–206.
36. Clementi M. Perspectives and opportunities for novel antiviral
treatments targeting virus ﬁtness. Clin Microbiol Infect 2008; 14: 629–
631.
1538 Clinical Microbiology and Infection, Volume 16 Number 10, October 2010 CMI
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1532–1538
